𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Inhibition of mitogen-induced lymphocyte blastogenesis by serum from tumor-bearing animals: Changes with tumor growth

✍ Scribed by D.E. Schumm; D.F. Billmire; H.P. Morris

Book ID
113145680
Publisher
Elsevier Science
Year
1976
Weight
550 KB
Volume
12
Category
Article
ISSN
0014-2964

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Adenocarcinoma-associated antigen: Enhan
Adenocarcinoma-associated antigen: Enhancement of tumor growth with serum from animals bearing adenocarcinoma
✍ Anwar A. Hakim 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 803 KB

## Abstract Why do tumors continue to grow in the presence of cell‐mediated immune reactions? When inoculated subcutaneously, 10^5^ viable spontaneous mammary adenocarcinoma cells produced solid tumors that progressively proliferated and eventually kilted all the recipient mice. During the first 10

Lymphocyte-mediated lysis of tumor cells
Lymphocyte-mediated lysis of tumor cells in vitro (ADCC), induced by serum antibodies from patients with urinary bladder carcinoma or from controls
✍ M. Troye; Y. Hansson; S. Paulie; P. Perlmann; H. Blomgren; B. Johansson 📂 Article 📅 1980 🏛 John Wiley and Sons 🌐 French ⚖ 694 KB

## Abstract IgG fractions from serum of patients with transitional‐cell carcinoma of the urinary bladder (TCC), patients with carcinoma of the prostate (CC) and healthy donors (HD) were tested for their capacity to induce antibody‐dependent lymphocyte‐mediated cytotoxicity (ADCC) to tumor cells in

Inhibition of tumor cell growth by antib
Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu
✍ Joanna Jasinska; Stefan Wagner; Christian Radauer; Roland Sedivy; Thomas Brodowi 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 166 KB

## Abstract The anti Her‐2/neu monoclonal antibody Trastuzumab has strong inhibiting effects on tumor growth __in vitro__ and __in vivo__ and is therefore used for immunotherapy in breast cancer patients. Due to necessity of frequent applications, however, cost intensiveness of Trastuzumab treatmen